Escobar Cervantes C

• Atrial Fibrillation Prevalence Rates and Its Association with Cardiovascular-Kidney-Metabolic Factors: SIMETAP-AF Study 2024-08-29
  Background and Objectives: Atrial fibrillation (AF) is the most frequent arrhythmia and the main cause of hospital admissions for cardioembolic stroke. The SIMETAP research project aims to update the prevalence rates of cardiovascular, renal, or metabolic factors and to evaluate their respective associations with factors that could be related. The present study aims to assess […]
  Antonio Ruiz-García
• Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study 2024-08-29
  Background: Scientific societies disagree on serum uric acid (SUA) thresholds for the diagnosis of hyperuricaemia (HU) according to epidemiological or physiochemical criteria (SUA ≥ 7.0 mg/dL for men and ≥6.0 mg/dL for women [HU-7/6]; SUA ≥ 7.0 mg/dL for both genders [HU-7/7], respectively). HU is not included among the diagnostic criteria for metabolic syndrome or […]
  Antonio Ruiz-García
• Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry 2024-08-28
  CONCLUSIONS: SMuRF-less patients with stable CAD have a substantial but significantly lower 5-year rate of CV death or non-fatal MI than patients with risk factors. The risk of CV outcomes increases steadily with the number of risk factors.
  Guillaume Roger
• SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination? 2024-07-11
  No abstract
  Carlos Escobar Cervantes
• Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study 2024-01-04
  CONCLUSIONS: About half of patients attended in primary care settings have hypertension in Spain. Patients with hypertension have a worse CV clinical profile than non-hypertensive patients, with greater association of CVRF and CVD. Around four out of ten patients do not achieve the recommended BP goals, and higher use of combination therapies is associated with […]
  Miguel A Prieto-Díaz
• Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation 2023-11-07
  INTRODUCTION: In addition to an increased risk of thromboembolic complications, patients with atrial fibrillation (AF) are at risk for vascular events. Consequently, complete vascular protection is warranted in these patients.
  Carlos Escobar-Cervantes
• Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study 2023-10-28
  Background and objectives: Arterial hypertension (HTN) is the leading preventable cause of atherosclerotic cardiovascular diseases (ASCVD) and death from all causes. This study aimed to determine the prevalence rates of HTN diagnosed according to the threshold diagnostic criteria 130/80 mmHg and 140/90 mmHg, to compare blood pressure (BP) control, and to evaluate their associations with […]
  Vicente Pallarés-Carratalá
• Should atrial fibrillation be considered a vascular disease? The need for a comprehensive vascular approach 2023-10-24
  INTRODUCTION: Atrial fibrillation (AF) cannot be considered an isolated disease. Patients with AF should be managed using a comprehensive approach that is not limited to stroke prevention.
  Carlos Escobar-Cervantes
• Prognosis of Systolic Pressure 130 to 139 According to Risk. A Prospective Cohort Study Between 1992 and 2019 2023-09-11
  CONCLUSIONS: In this primary prevention population of relatively young average age, untreated SBP of 130 to 139 mm Hg at low-CVR had long-term prognostic value and might benefit from stricter SBP targets. High-CVR patients had nonsignificant higher risk (limited sample size) but 4-fold greater risk when compared with low-CVR. Overall, results indicate the importance of […]
  Juan A Divison-Garrote
• Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study 2023-08-12
  CONCLUSIONS: This study reports that HF prevalence increases from 4.5% in the population over 50 years to 10% in the population over 70 years. The main clinical conditions that are HF-related are sedentary lifestyle, atrial fibrillation, hypertension, diabetes, low eGFR, stroke, and CHD.
  Antonio Ruiz-García
• Projected clinical benefits of dapagliflozin in patients with heart failure with preserved ejection fraction 2023-06-29
  Aims: To address the projected clinical benefits of dapagliflozin among patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). Methods: A multicenter, prospective, cohort study of patients ≥50 years admitted with HF to Spanish internal medicine departments. The projected clinical benefits of dapagliflozin were calculated from the DELIVER […]
  Manuel Montero-Pérez-Barquero
• Benefits of dapagliflozin in the whole spectrum of heart failure in clinical practice: the RICA registry 2023-06-29
  Aims: To determine the projected benefits of dapagliflozin after an acute heart failure (HF) event in Spain. Methods: A multicenter and prospective study that included subjects aged 50 years or older consecutively admitted with HF to internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were calculated via pooled analysis of the DAPA-HF […]
  Manuel Montero-Pérez-Barquero
• Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice 2023-06-29
  Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure (HF) with reduced ejection fraction in clinical practice in Spain. Materials & methods: This multicenter cohort study included subjects aged 50 years or older consecutively hospitalized for HF in internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were estimated […]
  Manuel Montero-Pérez-Barquero
• Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes 2023-06-28
  Type 2 diabetes (T2DM) is one of the main public health care problems worldwide. It is associated with a marked increased risk of developing atherosclerotic vascular disease, heart failure, chronic kidney disease and death. It is essential to act during the early phases of the disease, through the intensification of lifestyle changes and the prescription […]
  Almudena Castro Conde
• Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain 2023-05-28
  CONCLUSIONS: In Spain, most patients with dyslipidemia do not achieve the recommended LDLc goals because of an insufficient intensification of lipid lowering therapy. On the one hand, this is in part due to physicians misperception on preventive LDLc control and the need for repeated advice to patient, and, on the other, to the lack of […]
  Juan Cosín-Sales
• Hypercholesterolaemia control in Spain: The same situation with different regional realities 2023-04-29
  CONCLUSIONS: Even though the distribution of patients at high/very high CVR was similar between autonomous communities, inter-territorial differences were identified in the degree of achievement of LDL cholesterol therapeutic goal and use of lipid-lowering therapy.
  Juan Pedro-Botet
• Oral Sodium Chloride in the Prevention of Contrast-Associated Acute Kidney Injury in Elderly Outpatients: The PNIC-Na Randomized Non-Inferiority Trial 2023-04-28
  CONCLUSION: The incidence of CA-AKI was lower than expected. Although both regimens showed similar incidences of CA-AKI, the non-inferiority was not shown.
  Cecilia Suárez Carantoña
• Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization 2023-03-24
  INTRODUCTION: Worsening heart failure (HF) is associated with a high risk of death and HF hospitalization.
  Alberto Esteban Fernández
• Identifying the patient with heart failure to be treated with vericiguat 2023-03-10
  The pathophysiology of heart failure with reduced ejection fraction (HFrEF) is a complex process in which a number of neurohormonal systems are involved. Targeting only some of these systems, but not all, translates into a partial benefit of HF treatment. The nitric oxide-soluble guanylate cyclase (sGC)-cGMP pathway is impaired in HF, leading to cardiac, vascular […]
  Carlos Escobar Cervantes
• Multicenter prospective comparison of conventional and high-power short duration radiofrequency application for pulmonary vein isolation: the high-power short-duration radiofrequency application for faster and safer pulmonary vein ablation (POWER FAST III) trial 2023-02-22
  CONCLUSIONS: The results of the POWER FAST III could support the use of the high-power short-duration ablation in clinical practice.
  Sergio Castrejón-Castrejón